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HIV-1-neutralizing antibodies develop in most HIV-1-
infected individuals, although highly effective anti-
bodies are generally observed only after years of
chronic infection. Here, we characterize the rate of
maturation and extent of diversity for the lineage
that produced the broadly neutralizing antibody
VRC01 through longitudinal sampling of peripheral
B cell transcripts over 15 years and co-crystal
structures of lineage members. Next-generation
sequencing identified VRC01-lineage transcripts,
which encompassed diverse antibodies organized
into distinct phylogenetic clades. Prevalent clades
maintained characteristic features of antigen recog-
nition, though each evolved binding loops and disul-
fides that formed distinct recognition surfaces. Over
the course of the study period, VRC01-lineage clades
showed continuous evolution, with rates of 2 sub-
stitutions per 100 nucleotides per year, comparable
to that of HIV-1 evolution. This high rate of antibody
evolution provides a mechanism by which antibody
lineages can achieve extraordinary diversity and,
over years of chronic infection, develop effective
HIV-1 neutralization.
INTRODUCTION
HIV-1-neutralizing antibodies to autologous virus develop within
weeks or months of infection (Albert et al., 1990; Richman et al.,
2003; Wei et al., 2003), with serum neutralization generally
evolving over time to gain increased potency and breadth (Gray
et al., 2011; Mikell et al., 2011). In a study of 200 chronically470 Cell 161, 470–485, April 23, 2015 ª2015 Elsevier Inc.HIV-1-infected individuals, serum from 50% of studied donors
contained antibodies capable of neutralizing 50% of HIV-1
strains (Hraber et al., 2014). A subset of these individuals de-
velops potent and broadly reactive antibodies (Gray et al.,
2011; Li et al., 2007; Mikell et al., 2011; Walker et al., 2010; Wu
et al., 2006). Isolation and characterization reveal these broadly
neutralizing antibodies to have one or more unusual features
including long or protruding heavy-chain third complemen-
tarity-determining regions (CDRH3s) (Burton et al., 1994; Walker
et al., 2009; Zhou et al., 2007), domain swapping (Calarese et al.,
2003), unusual post-translational modifications such as tyrosine
sulfation (TyrS) (Huang et al., 2004; Pancera et al., 2010; Pejchal
et al., 2010), poly or autoreactivity (Haynes et al., 2005), extensive
somatic hypermutation (SHM) (Scheid et al., 2011; Walker et al.,
2011;Wuet al., 2010, 2011), or dependence on framework region
contacts (Klein et al., 2013). These characteristics highlight the
extensive maturation process necessary for most antibodies to
achieve effective HIV-1 neutralization (Burton et al., 2005; Klein
et al., 2013; Mascola and Haynes, 2013; Scheid et al., 2009).
To understand how effective neutralization develops, we and
others have investigated the ontogenies of neutralizing antibody
lineages using monoclonal antibodies (mAbs) isolated from
individual B cells (Bonsignori et al., 2012; Scheid et al., 2011;
Walker et al., 2011), next-generation sequencing (NGS) of
cross-sectional samples (Wu et al., 2011; Zhou et al., 2013;
Zhu et al., 2012, 2013), and NGS of longitudinal samples studied
from time of infection (Doria-Rose et al., 2014; Liao et al., 2013).
While these studies often focused on revealing the unmutated
common ancestors (UCAs) of neutralizing antibody lineages
and early antibody maturation, questions remain about the
long-term and continuing development of antibody lineages.
What is the scope of B cell development in a broadly neutralizing
antibody lineage? What are the rates, compositions, extents,
and continuities of lineage evolution? What biological mecha-
nisms underlie the development of HIV-1 neutralization?
Here, we investigate the VRC01-antibody lineage, which tar-
gets the site of CD4 engagement on HIV-1 (Wu et al., 2010;
Zhou et al., 2010) and is a member of a class of antibodies (the
VRC01 class), which share similar structural and genetic charac-
teristics (West et al., 2012; Wu et al., 2011; Zhou et al., 2013). We
identified dozens of VRC01-lineage antibodies from one donor
and describe characteristics of this lineage as it evolved over
the course of 15 years. Overall, these results delineate the scope
of evolutionary diversity for a persistent antibody lineage. Anti-
body lineage characteristics identified here—such asmulti-clade
divergence and a high rate of evolution—may be common to
effective HIV-1-neutralizing antibodies and provide insights into
the immunological mechanisms that enable their development.
RESULTS
39 Probe-Identified Antibodies Define Three
VRC01-Lineage Clades
The broadly neutralizing antibodies VRC01, VRC02, and VRC03
were previously isolated from an August 2008 sample of donor
45 peripheral bloodmononuclear cells (PBMCs), using the resur-
faced stabilized core 3 (RSC3) probe (Wu et al., 2010). Fromaddi-
tional 2008 samples, other probes were subsequently used
to isolate five more VRC01-class antibodies: NIH45-46, NIH45-
177, NIH45-243, VRC06, and VRC06b (Li et al., 2012; Scheid
et al., 2011). All eight of these antibodies appeared to be somatic
variants from a single VRC01 lineage (Zhou et al., 2013).
To gain insight into the scope of the VRC01 lineage, we per-
formed RSC3-specific B cell sorting on PBMCs from April 2002
and August 2008 time points to identify additional lineage mem-
bers (Figure 1A, left and right). We also performed B cell sorting
with a modified gp120 outer-domain probe (Joyce et al., 2013)
on PBMCs from January 2008 (Figure 1A, middle). Five anti-
bodies were recovered from the 2002 sample, including a
new VRC01-lineage antibody, VRC08, which was substantially
different from those identified previously. The CDR H3 of
VRC08 was 23 amino acids in length by Kabat definition, sub-
stantially longer than those of VRC01 and VRC07 (12 and 16
amino acids, respectively) or VRC03 and VRC06 (14 and 15
amino acids, respectively) (Figure 1B). We assessed neutraliza-
tion by VRC08 against 195 Env pseudoviruses. VRC08 displayed
breadth and potency similar to VRC01 (Figure 1C; Table S1). In
addition to VRC08, several other closely related antibodies
were identified. In all, we identified 31 newneutralizing antibodies
fromdonor 45, all with naturally paired heavy and light chains and
derived from the same origin genes (Figure 1B; Figure S1).
Amaximum-likelihoodphylogenetic treewasconstructed from
the concatenated heavy- and light-chain nucleotide sequences
of the 39 VRC01-lineage antibodies (Figure 1D); they segregated
into three major clades, termed clade 01+07, clade 03+06, and
clade 08. Sequence differences within clades were under 25%,
while differences exceeded 50% between clades (Figure 1E),
and CDR H3 lengths varied from 12 to 23 amino acids.
Tracking Potential VRC01-Lineage Sequences in
Longitudinal Samples
To gain a more complete understanding of the VRC01 lineage
and its development, we used NGS to identify potential lineagemembers over 15 years. The first sample available was from
March 1995, well after the diagnosis of HIV-1 infection in 1990.
Ten samples were analyzed, extending to December 2009. Dur-
ing this 15-year period, donor 45 maintained a relatively stable
plasma viral load of around 10,000 copies/ml and a CD4+
T cell count >500 cells/ml without anti-retroviral therapy (Table
S2A). cDNA libraries from each time point, corresponding to
the transcripts of 3–5 million PBMCs, were used as templates,
and 50 gene family-specific primers were used to amplify VH1
genes or Vk3 genes, with 30 primers for both immunoglobulin
M (IgM) and immunoglobulin G (IgG) or immunoglobulin k (Igk)
constant regions. We estimate that each longitudinal sample
contained 75–125,000 VH1-family-derived B cells and 100–
160,000 Vk3-family-derived B cells. 454 pyrosequencing, with
either a half- or full-454 chip, generally yielded between a quarter
million to a million raw reads for each heavy- or light-chain reac-
tion, for each time point (Figure 2).
A heavy-chain-specific bioinformatics pipeline with multiple
computational sieves was used to identify VRC01-lineage tran-
scripts and to classify them into closely related groups of se-
quences based on CDR H3 identity (Figure S2A, bottom panels).
We utilized a modified cross-donor analysis algorithm and
applied several levels of data quality filtering and de-replication
with a 97.25% identity threshold (Extended Experimental Proce-
dures). These quality filters ameliorated known 454 errors and
reduced the number of unique sequences. The effect of each
data-filtering step on the number of retained sequences is
shown in Table S2B. Similarly, a light-chain-specific pipeline
was used to identify and classify VRC01-lineage light-chain tran-
scripts (Figure S2B, bottom panels). As with the heavy chains,
we applied data-quality filters (Figure 2B, bottom panels, and
Table S2B).
Wewere able to track the evolution of each clade of the VRC01
lineage through the positions of clusters of closely related
sequences on identity/divergence (I-D) plots over time (Figure 2;
Figures S2C–S2F). The positions of these clusters at successive
time points revealed the persistence and continued SHMof each
clade, with a typical increase of 5%–10% in divergence over
10 years and a maximal sequence identity around the time of
isolation of the referent antibody.
Validation of Functional Antibody Clades and Definition
of the VRC01 Lineage
For both heavy and light chains, we found large groups of se-
quences that were divergent from all probe-isolated antibodies
but shared VRC01-lineage origin genes. We previously used
functional complementation between heavy and light chains to
confirm functionality and membership in the VRC01 class (Wu
et al., 2011; Zhu et al., 2013). Importantly, reconstitution of unre-
lated antibody heavy chains with a VRC01 light chain, even using
heavy chains with high predicted VRC01 structural compatibility,
failed to neutralize HIV-1 in ten out of ten trials (Wu et al., 2011).
To assess the thousands of divergent B cell transcripts from
NGS, we clustered them into groups: heavy chains were clus-
tered based on CDR H3 identity into CDR H3 groups; light
chains, which have short CDR L3s, were clustered based on
overall sequence identity into light-chain variable region (VL)
groups. We focused on the most populous groups (thoseCell 161, 470–485, April 23, 2015 ª2015 Elsevier Inc. 471
Figure 1. VRC01-Antibody Lineage: 39 Probe-Identified Antibodies Define Three Distinct Clades
(A) Isolation of antigen-specific antibodies by sorting of donor 45. B cells were probed either with RSC3 and its DI371 mutant DRSC3 or with a modified outer
domain OD4.2 protein HG3.2 and its D368R mutant DHG3.2. Indicated in red is the percentage of total IgG+ B cells defined as probe-specific in each gate.
(B) Heavy- and light-chain sequence analysis for six representative antibodies, two from each clade. Residues flanking the CDR H3 are shown in gray.
(C) VRC08 neutralization dendrogram of 195 HIV-1 Env pseudoviruses with branches colored by potency.
(D) Maximum-likelihood tree of VRC01-lineage antibodies from donor 45, rooted on the germline V gene sequence. Antibody clades, 01+07, 03+06, and 08 are
indicated.
(E) Pairwise sequence difference of heavy- (left) and light- (right) chain variable domains for the six representative antibodies. Intra-clade differences are boxed.
See also Figure S1 and Table S1.
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Figure 2. NGS-Identified VRC01-Lineage Transcripts in Donor 45 over 15 Years
(A) Clade-specific identity-divergence plots from heavy-chain longitudinal samples. Large example plot is shown at left for clade 08. Sequence divergence from
the assigned germline V gene (x axis) and sequence identity to the VRC08 heavy-chain variable domain (y axis). Positions of the six representative antibodies from
Figures 1D and 1E are shown as red X’s. Identity-divergence plots for ten longitudinal time points (right). Time points and fraction of a 454 chip used for NGS are
indicated at the top. The top row shows a heatmap for positions of all 454 sequences. The total number of sequences is indicated at the right borders. Themiddle
row shows the distribution of cross-donor positive sequences as blue dots, with gray contours indicating raw sequences. The total number of cross-donor
positives is displayed in blue. The bottom row shows the distribution of sequences in the same CDR H3 group as any probe-isolated antibody from that clade.
Yellow dots indicate raw sequences within the CDR H3 groups, while purple dots show the subset of those sequences that survived quality-control filtering. The
total numbers of raw and curated sequences in the CDRH3 groups are indicated in yellow and purple, respectively; blue contours indicate cross-donor positives.
(B) Clade-specific identity-divergence plots from light-chain longitudinal samples. The same analyses are shown as for (A), except that the middle row shows the
distribution of sequences with a 5-amino-acid CDR L3. Because sequences are clustered across all ten time points to determine the final curated sequences
(Extended Experimental Procedures), groups of in-clade sequences (yellow dots) with high identity to the referent antibody (e.g., in the 01/2007, 07/2007, and 01/
2008 time points)may appear to have resulted in no surviving high-quality sequences (no purple dots). In actuality, the representative sequence in the final curated
set has simply been chosen from a different time point (e.g., 07/2006).
See also Figure S2 and Table S2.containing at least 300 raw heavy-chain sequences or 75 raw
light-chain sequences) and chose two representative sequences
for testing from each heavy- and light-chain group (Figure 3;
Tables S3A and S3B) (Extended Experimental Procedures).
Many of these selected sequences were observed at multiple
time points (Tables S3C and S3D). For heavy chains, representa-
tive sequences from 19 CDR H3 groups neutralized HIV-1 when
reconstituted with VRC01 or VRC03 light chain (Figure 3A; Table
S3A). Two of these groups, H.I and H.N, appeared to use
non-lineage matching JH genes (Extended Experimental Proce-
dures), though the identity of the JH gene was uncertain due to
the high level of SHM (35% and 25% diverged from VH1-2,
respectively). These ambiguous groups were analyzed sepa-rately from the rest of the VRC01 lineage. For light chains, 18
VL groups neutralized HIV-1 when reconstituted with VRC01
or VRC03 heavy chain (Figure 3B; Table S3B). One group, L.C,
was composed of multiple unrelated lineages using various Vk
and Jk genes and was not included in analysis of the VRC01
lineage.
Although they shared the same germline origin genes (VH1-2
and JH1), the diverse heavy-chain sequences identified could
derive from a single lineage or multiple lineages. We observed
that the 39 probe-identified antibodies from donor 45 all con-
tained a cysteine at position 98 (99 in some sequences due to
a 1-aa insertion). This cysteine is not a required feature of the
VRC01 class, as VRC01-class antibodies from other donors doCell 161, 470–485, April 23, 2015 ª2015 Elsevier Inc. 473
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Figure 3. Many Bioinformatically Identified Sequences Not Closely Related to Probe-Identified Antibodies Neutralize Diverse Viral Strains
(A) Representative sequences from the most prevalent CDR H3 groups were synthesized, reconstituted with VRC01 and VRC03 light chains, and tested for
neutralization. CDRH3 groups confirmed for neutralization were assessed for sequence identity (Figure 4A) to each other andmerged into clades (center column).
(legend continued on next page)
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not contain such a residue. We therefore used this signature
cysteine to assess membership in the VRC01 lineage. Of 1,041
curated NGS sequences assigned to the VRC01 lineage, six
did not contain the cysteine while 1,035 did (99.4%). By contrast,
of the remaining VH1-2-derived NGS reads from this donor
not assigned to the VRC01 lineage, 104,223 sequences did not
have this signature cysteine, while 4,641 did (4.3%; p <
0.0001) (Figure S3B).
To examine the relationship among the neutralizing groups
with VRC01-lineage origin genes, we calculated the full-length
pairwise identities of the validated representative sequences
and probe-identified antibodies. Pairwise identity matrices,
grouped by similarity, are shown as heatmaps for heavy and light
chains in Figures 4A and 4B, respectively. The CDR H3 and VL
groups clustered into higher-order units. Critically, correspon-
dence with maximum-likelihood phylogenetic trees (Figure 4C)
confirmed that the clusters of neutralizing groups define phylo-
genetic clades similar to the three originally defined by the
probe-isolated antibodies (Figure S4).
Known heavy- and light-chain pairings from the probe-identi-
fied antibodies were used to approximately align the heavy and
light maximum-likelihood phylogenetic trees. Temporal preva-
lence was calculated from the number of non-redundant
NGS reads assigned to each of the clades (Figure 4C, middle)
(Extended Experimental Procedures). For each clade, preva-
lence of reads waxed and waned independently over time. For
example, clades H5 and L3 remained at a fairly constant level,
while clade 01+07 was more prevalent at intermediate time
points, and clades H3, H4, and 08 increased in prevalence at
later time points. For the three probe-identified clades (01+07,
03+06, and 08), heavy- and light-chain prevalence should corre-
late temporally; in practice, these correlations ranged from 0.05
to 0.91, suggesting possible sampling issues for clade 03+06.
Overall, the NGS of peripheral VRC01-lineage transcripts pro-
vided a large number of sequences (Table S2B), allowing for
much greater definition of VRC01-lineage diversity than was
possible with the 39 probe-identified antibodies (Figure 1). Mul-
tiple branches surround and embed the original three clades in
a more diverse phylogenetic tree with three additional heavy-
chain clades and two additional light-chain clades (Figure 4C).
The greater number of NGS sequences permitted quantification
of the initial and newly identified clades over time, thus illumi-
nating the scope, diversity, and development of the lineage.
Conservation of Antigen-BindingModewithin the 01+07
Clade of the VRC01 Lineage
The extraordinary sequence diversity of the VRC01 lineage
revealed by NGS could represent possibilities ranging from sig-
nificant changes in mode of antigen recognition to sequence
alteration with a conserved binding mode. To delineate between
these two extremes, we evaluated the longitudinal maintenanceTwo groups with non-matching J gene assignments (gray rows) were excluded
sentative (if any), assigned V and J genes, and themost neutralizing representative
potency for both VRC01 and VRC03 light-chain pairings are provided against se
(B) The same information as shown in (A), for the most prevalent light-chain-vari
chains from VRC01 and VRC03. Group L.C, shown in gray, consisted of multiple
See also Figure S3 and Table S3.of a previously defined set of VRC01 signature residues (Zhou
et al., 2013) and the structural conservation of recognition by a
clade over time. While only 60%–70% of unrelated VH1-2 se-
quences conserved at least eight of ten positions in the signa-
ture, nearly all sequences from four of the six heavy-chain clades
did so (Figures 5A and 5B; Figure S5A). For clade 01+07, we
determined co-crystal structures of an antibody from 1995 and
compared these to the co-crystal structure of an antibody iden-
tified from the 2008 time point (Figures 5C–5F) (Diskin et al.,
2011). For the 1995 antibody, co-crystal structures were deter-
mined with extended cores both from the autologous gp120
(from donor 45) and from a heterologous gp120. By contrast,
the antibody from the 2008 time point was determined in com-
plex only with a heterologous gp120 extended core (Figure 5E;
Table S4). We calculated the root-mean-square deviations
(rmsds) for the variable domains in the various crystal structures:
there was a 0.38 A˚ rmsd on Ca of the variable domains between
the two 1995 antibody structures; between the 1995 structures
and 2008 structure, the rmsd was 0.45 and 0.50 A˚ for the
same gp120 and different gp120s, respectively. Epitope recog-
nition was highly conserved between the 1995 and 2008 anti-
bodies, which interact with a similarly sized area of gp120
(1,185 A˚2 and 1,166 A˚2 for the 1995 antibody, and 1,247 A˚2 for
the 2008 antibody) with approximately 95% of the contact area
conserved (Figure S5B). The antibody paratope was also highly
similar but showed an increase in size for the 2008 antibody
compared to the 1995 antibody (1,177 A˚2 and 1,136 A˚2 for the
1995 antibody, and 1,458 A˚2 for the 2008 antibody). This differ-
ence in the paratope was largely due to reduced inner domain
and bridging sheet interactions for the 1995 antibody compared
to the 2008 antibody, and the increase in recognized surface
could be attributed to SHM, especially Ser74Tyr and Ser99BArg
in the heavy chain.
We assessed gp120 binding of a VRC01 variant with the germ-
line sequence in the heavy- and light-chain variable regions, but
mature CDR3 regions (since the original unmutated versions
of the CDR3 junctions cannot be accurately inferred). Such
germline-reverted variants of VRC01-class antibodies have
been reported to lack gp120 binding activity (Jardine et al.,
2013; McGuire et al., 2013; Zhou et al., 2010). Nonetheless,
here we show binding to the early autologous gp120 molecule,
d45-01dG5 (GenBank accession number JQ609687) (Wu et al.,
2012) (Figure S5C) with affinity in the micromolar range. The
affinity of the VRC01 lineage for this gp120 improved to sub-
nanomolar levels for the 1995 and 2008 antibodies. These later
antibodies were also able to interact with many more autologous
and heterologous gp120 strains. Overall, the structures indicate
that the 20 changes in amino acid sequence due to SHM
between 1995 and 2008 antibodies enhance antibody-antigen
interactions. However, antibody recognition over the 13-year
time period remains highly similar, with core interactive residuesfrom further analysis. Total sequences in each group, probe-identified repre-
and its CDRH3 sequence (left columns) are shown. Neutralization breadth and
lected HIV-1 viruses from clades A, B, and C (right columns).
able region groups tested for neutralization after reconstitution with the heavy
unrelated clones and was excluded from further analysis.
Cell 161, 470–485, April 23, 2015 ª2015 Elsevier Inc. 475
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Figure 4. Heavy and Light Chain of the VRC01 Lineage Exhibit Multi-Clade Phylogenetic Organization and Concordance
(A) Heatmap showing pairwise sequence identities for heavy chains of probe-identified antibodies and validated neutralizing heavy-chain sequences sorted by
overall prevalence (among final curated sequences). Groups with high identity and similar prevalences were merged into clades, shown at left.
(legend continued on next page)
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mostly unchanged. Thus, despite extraordinary sequence varia-
tion, the VRC01 lineage maintains a largely conserved binding
mode.
Rate of VRC01-Lineage Evolution
Since somatic variants of the VRC01 lineage derived from a
common precursor B cell, it is possible to determine evolutionary
rates for thematuration of the lineage aswell as for eachclade. To
quantify the rate of lineage evolution,weusedBEASTv1.8 (Drum-
mondandRambaut, 2007),whichhasbeenusedpreviously toes-
timate evolutionary rates for sequences from various population
types, including HIV (Alizon and Fraser, 2013; Vrancken et al.,
2014). It is important to note that evolutionary rate is not equiva-
lent to the increase in germline divergence, as it describes the
overall rate of substitutions, not all of which result in increased
germline divergence. For example, the same site can mutate
multiple times, including reverting to the original nucleotide.
Over the entire time period of the study, VRC01-lineage heavy
and light chains had similar evolutionary rates of 2.1 and 1.6 sub-
stitutions per 100 nucleotides per year, respectively (Figure 6A,
green and blue panels). This rate of mutation was similar to the
rate of 1.5 substitutions per 100 nucleotides per year that we
determined for the Env gene in this donor (Figure 6A, red panel)
based on previously determined viral genome sequences (Wu
et al., 2012), and the rate of 1.9 substitutions per 100 nucleotides
per year determined for previously reported Env sequences from
donor CH505 (Liao et al., 2013). These results are also consistent
with previous estimations of Env evolution rates, which have
ranged from 0.69 to 1.4 substitutions per 100 nucleotides per
year (Alizon and Fraser, 2013; Chaillon et al., 2012; Vrancken
et al., 2014). We also calculated evolutionary rates for each clade
independently (Figure 6A, green and blue panels). Although
clades H4 and L3 showed rates somewhat higher than the other
clades, evolutionary rates for all of the VRC01 cladeswere similar
at approximately two substitutions per 100 nucleotides per year.
To provide an overview of the VRC01 lineage and its devel-
opment, we produced maximum-likelihood phylogenetic trees
with curated sequences, annotated with evolutionary rates for
the VRC01-lineage clades (Figure 6B). Each sequence is colored
based on its apparent ‘‘birthday’’—the time point from which it
was first identified in the NGS data. Importantly, advancing time
(indicatedby theprogressionof colors) andadvancingmaturation
(indicated by branch positions) were consistent, in that later tran-
scripts appeared at greater radial distances on the tree.
Evolutionary Rate of the VRC01LineageAppears toSlow
To compare the evolutionary rates of the VRC01 lineage with
other broadly HIV-1-neutralizing antibody lineages, we retrieved
CAP256-VRC26 (Doria-Rose et al., 2014) and CH103 (Liao et al.,
2013) lineage NGS sequences from GenBank. Average germline(B) Heatmap for light chains of probe-identified antibodies and validated neutral
(C) Maximum-likelihood phylogenetic trees for heavy-chain (left) and light-chain (
structure of the trees, which have similar overall topology. Temporal prevalence (m
frame junction and no stop codons (but without manual curation) at each time poin
anchored by probe-identified antibodies, the correlation of heavy- and light-chain
at each time point is calculated from curated sequences.
See also Figure S4.divergence for these lineages increasedmore rapidly than for the
VRC01 lineage (Figure S6A). We also found an evolutionary rate
of 11 and 9.3 substitutions per 100 nucleotides per year, respec-
tively, for the CAP256-VRC26 lineage heavy and light chains,
and 13 and eight substitutions per 100 nucleotides per year,
respectively, for the CH103 lineage (from donor CH505) heavy
and light chains (Figure 6C, purple panel). Each of these early
rates was 5-fold higher than that observed for the VRC01 line-
age, which was at a much later stage in its development.
Since these rate differences in principle could arise from differ-
ences between the donors, we undertook direct rate calculations
on donor 45 datasets comprising the beginning (1995–2002) and
end (2006–2009) of the study period (Figure 6C, green and blue
panels). For aggregate data, including all clades, the evolu-
tionary rate was higher for the early time period than the later
one (2.1 versus 1.6 substitutions per 100 nucleotides per year).
Although this difference was not statistically significant, it is
consistent with the hypothesis that antibody SHM occurs at a
faster rate during the early phase of lineage development. Simi-
larly, when data from each clade were considered separately,
the calculated rate was in all cases higher for the early time
period than the later one, further supporting the idea that evolu-
tionary rates slowed over time.
As a third test for the slowing of evolutionary rates, we used the
BEAST package to infer the date of the most recent common
ancestor sequence for each lineage. If evolutionary rate were
stable over time, we would expect this extrapolation to give a
reasonable estimate (Smith et al., 2009). For the VRC01 lineage,
the most recent common ancestor was estimated to have
occurred for heavy chain in 1971 and for light chain in 1979
(Figure S6B). Although the exact date at which donor 45 was
infected is unknown, the inferred dates are implausible, as the
AIDS epidemic began in the early 1980s. Similarly, the most
recent common ancestor of the CAP256-VRC26 lineage was
calculated to have occurred in early 2005 (Figure S6C), although
the UCA of that lineage is known to have appeared sometime in
March 2006 (Doria-Rose et al., 2014). The same inconsistency is
also observed for the CH103 lineage (Liao et al., 2013) (Fig-
ure S6D). The consistent prediction of common ancestors at
impossibly or implausibly early dates suggests that the evolu-
tionary rate was faster earlier in lineage development. The fact
that this was observed for the younger CAP256-VRC26 and
CH103 lineages, as well, implies that this slowing begins almost
immediately.
Thus, three distinct lines of evidence support the idea that
SHM persists over an extended period of time, but evolutionary
rate slows as an antibody lineage matures. Overall, clades within
the VRC01 lineage had similar evolutionary rates. Rates for other
lineages are not similar and varied over at least a factor of 5 be-
tween fast-early and slower-late lineage development. Studiesizing light-chain sequences, produced as in (A).
right) sequences. The clades described in (A) and (B) can be clearly seen in the
iddle) is charted for each clade as the fraction of unique sequences with an in-
t, which are assigned to that clade. For clades 01+07, 03+06, and 08, which are
temporal prevalence is shown (boxes). The average divergence for each clade
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Figure 5. Conservation of VRC01+07 Clade Recognition over 15 Years of Chronic Maturation
(A) Percentage of curated sequences in each clade conserving at least eight of the ten-residue heavy-chain signature amino acids of VRC01-class antibodies.
Bars are not shownwhere data were unavailable for a particular clade and time point. Nearly all sequences in four of six heavy-chain clades conserve at least eight
of the ten positions, compared to only 60%–70% of unrelated VH1-2-derived sequences (gray bars). Clades H3 (dark green) and H4 (orange) mutate away from
the signature over the course of the study.
(B) Sequence logos of the VRC01 class signature positions for each clade. Residues colored in blue do not match the defined signature. Note, nine of the ten
signature residues are contained in the VH1-2 germline. Thus, although in the non-VRC01-lineage sequences the dominant residue at each position matches the
signature, there is variationat almost everyposition, andany individual read is likely to havemore than two residuesmutated (A). For VRC01sequences, by contrast,
there is strong conservation at any given position (even those that are mutated away from the signature), and relatively few positions have any variation at all.
(C) Longitudinal phylogenetic trees of clade 01+07 sequences for heavy chain (left) and light chain (right). The color of each sequence corresponds to the date at
which it is first identified in the NGS data.
(D) Sequence alignment of heavy-chain (top) and light-chain (bottom) sequences from temporally diverse members of the 01+07 clade showingmutation from the
germline V gene.
(E) Crystal structures of autologous (blue, top left) or heterologous (pale yellow, top middle and top right) gp120s determined in complex with clade 01+07
antibodies (bottom). The complexes have been rotated to show the interacting surfaces on each molecule. Contacts made by 45-VRC01.H01+07.O-863513/45-
VRC01.L01+07.O-110653 (NGS-derived sequences from 1995, bottom left and bottom middle) are colored in green, while those made by NIH45-46 (isolated
from 2008, bottom right) are shown in red. Heavy-chain contacts are in the darker shade. These structures show a common bindingmode, with amodest increase
in buried surface area from the 1995 to the 2008 antibodies when bound to heterologous gp120.
(F) Antibody structures from (E) shown in ribbon format, with residues mutated from the germline V gene (top) or the 1995 sequence (bottom) shown in stick
representation.
See also Figure S5 and Table S4.
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Figure 6. Rates of Evolution and Extents of Divergence for Clades of the VRC01 Lineage over 15 Years of Chronic Infection
(A) Point estimates and 95%highest probability density of evolutionary rates for heavy- (green panel) and light-chain (blue panel) transcripts of the VRC01 lineage,
shown for the lineage overall and individual clades, calculated from subsets of the curated sequence set. Dashed line represents the rate calculated for HIV-1 Env
in donor 45. Evolutionary rates for Env for HIV genomes isolated from both donor 45 and donor CH505 (red panel) are comparable to the evolutionary rate of the
VRC01 lineage, calculated from deposited sequences for those datasets.
(B) Heavy- (left) and light-chain (right) phylogenetic trees for curated sequences from the VRC01 lineage annotated to showpoint estimates of evolutionary rate for
each clade. Trees are shown as ‘‘birthday’’ trees, with each sequence colored to show the time point at which it was first observed. Later observation times
(warmer colors) and greater maturation (larger radial distances) were consistent.
(C) Point estimates and 95% confidence intervals of evolutionary rate for VRC01 lineage transcripts calculated separately for the beginning (1995–2002) and end
(2006–2009) of the study period (green and blue panels). Sequences used are subsets of those described for (A). In each case, the earlier rate is faster than the
later one, though the differences do not reach statistical significance. For comparison, evolutionary rates of early HIV-1-neutralizing antibody lineages from
donors CH505 and CAP256 (purple panel) are 5-fold higher, as calculated from deposited sequences of those. Additionally estimation of least common an-
cestors for each lineage are consistently earlier than known or plausible dates (Figure S6), suggesting that evolutionary rates were faster earlier in the history of
each lineage.
See also Figure S6.of the early lineages CAP256-VRC26 and CH103 suggested that
this slowing begins very early in lineage development.
VRC01-Lineage Recognition: Epitope Variation,
Disulfide Patterns, and Probed Surfaces
The continuous mutation observed over years of chronic
infection provides a means to achieve the extraordinary levelsof SHM observed with many of the anti-HIV-1 broadly
neutralizing antibodies. For the VRC01 lineage, this diver-
gence reaches over 30% for individual lineage members rela-
tive to the germline genes, although the variance between
individual members of the lineage is considerably greater,
with multiple clades evolving in a multiplexed manner
(Figure 6B).Cell 161, 470–485, April 23, 2015 ª2015 Elsevier Inc. 479
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Figure 7. The VRC01 Lineage Evolves Divergent Recognition Loops and CDR H3 Disulfides
(A) Heavy-chain phylogenetic tree for probe-identified antibodies and validated neutralizing sequences of the VRC01 lineage annotated for the acquisition of
molecular features.
(B) Epitope, recognition, and paratope for representative VRC01 clades. Structures of VRC01-lineage antibodies in complex with gp120 are shown with CDR H1
in blue, CDR H2 in yellow, CDR H3 in red, FR3 in cyan, and light chain in dark gray. These are displayed on the gp120 surface for epitope (left column), as colored
regions of a ribbon diagram for recognition (middle column), and the CDR H3 and associated cysteines are highlighted in paratope (right column). For clade H5
(top row), the NGS-identified heavy chain 45-VRC01.H5.F-185917 paired with the light chain from VRC01 is shown. NGS-derived heavy chains in clades 03+06
and 08 were paired with VRC03 and VRC08 light chains, respectively.
See also Figure S7 and Table S5.Several of the newly identified VRC01-lineage clades showed
remarkable differences. For example, the VRC08 CDR H3 is 11
residues longer than that of VRC01 and contains three additional
cysteines. To understand the variation of structural recognition
of VRC01-lineage antibodies between different clades, we crys-
tallized the antigen-binding fragments (Fabs) of representative
antibodies from each clade in complex with HIV-1 gp120. Repre-480 Cell 161, 470–485, April 23, 2015 ª2015 Elsevier Inc.sentative antibodies were chosen based on their expression
level (>5 mg/l), neutralization potency (Figure 3), and phyloge-
netic placement (Figure 7A). From a total of ten antibodies, six
formed crystals with extended core gp120, which diffracted
beyond 3.5 A˚; structures of these were solved by molecular
replacement, and structural features of their recognition were
analyzed.
New structures included two from the 03+06 heavy-
chain clade (VRC06b and 45-VRC01.H03+06.D-001739; for
NGS-defined antibodies we use the nomenclature ‘‘donor-line-
age.[H/L]clade.time-point-read_number’’ for heavy and light
chains), three from the 08 heavy-chain clade (VRC08, VRC08c,
and 45-VRC01.H08.F-117225), and one from the H5 heavy-
chain clade (45-VRC01.H5.F-185917). We analyzed these
structures along with previously determined antibody-gp120
structures from donor 45 comprising those of VRC01, VRC03,
NIH45-46, and VRC06 (Diskin et al., 2011; Georgiev et al.,
2013; Wu et al., 2011; Zhou et al., 2010). When gp120s were
superimposed, modes of gp120 recognition by the variable
domains of the donor 45 antibodies resembled each other,
with the consensus/shared framework region of heavy chains
(rmsds = 0.46–2.41 A˚) (Table S5) showing moderately greater
diversity than that of light-chain-variable domains (rmsds =
0.36–1.65 A˚) (Table S5). While intra-donor differences between
common/consensus framework regions were not significantly
different from the inter-donor differences for VRC01-class anti-
bodies from different donors, two antibody heavy-chain regions
showed substantial clade diversity: the CDR H3 and the heavy-
chain-framework region 3 (FR3) (Figure 7B). The clade 08 CDR
H3 loop (23 amino acids) extends toward the inner domain of
gp120 and contributes 35% and 70%more binding surfaces
on gp120 than CDR H3 loops of 01+07 and 03+06 clades,
respectively (Figure 7B; Table S5). Unlike the CDR H3 of clade
08, the CDRH3s of clade 03+06 and clade H5make substantially
less contact with the inner domain of gp120 (130 A˚2 for clade
03+06, 200 A˚2 for clade H5, and 450 A˚2 for clade 08). Mean-
while, clade 03+06 antibodies are unique among antibodies of
the lineage for their extended FR3s, the result of a seven amino
acid insertion. These extended FR3s provide 1.5-, 2.5-, and
4.5-fold more binding surface on gp120 V1/V2 stem region
than FR3s of clades 01+07, 08, and H5, respectively (Table
S5), and induce conformation of the V1V2 region different from
that of other antibody-gp120 structures (Figure S7A). Because
antibody-Env complexes determined here were in the mono-
meric gp120 core context, we docked antibodies in the recently
determined structure of trimeric BG505 SOSIP (Julien et al.,
2013; Lyumkis et al., 2013; Pancera et al., 2014). The extended
FR3s were spatially proximal in the trimeric context to V1V2 (res-
idues 203–206) and V3 (residues 314–318) of the neighboring
protomer (Figure S7B). Small rearrangements could potentially
allow for energetically favorable contact, with positive V3 inter-
acting electrostatically with negatively charged FR3 insertions.
In terms of the large CDR H3 alterations, these projected onto
the inner domain and did not interact with neighboring proto-
mers. However, the CDR H3 of VRC08c makes potential con-
tacts with helix-a0 of the neighboring gp120 (Figure S7C).
Notably, the disulfide bonding patterns in the CDR H3 loops
vary between clades (Figure 7B). 01+07 clades have an interloop
disulfide bond between Cys98 (CDR H3) and Cys32 (CDR H1).
Clade 03+06 and clade H5 have a single disulfide bond between
Cys98 and Cys100A, Cys98 and Cys100C, respectively. Clade
08 has two pairs of intra disulfide bonds (Cys98-Cys100J
and Cys99-Cys100E) within the CDR H3 loop, which likely
adds structural rigidity to this CDR H3, which is approximately
ten residues longer than observed in most of the other clades.Although CDR H3 cysteine diversity has been observed before
with bovine antibodies (Wang et al., 2013), the bovine mecha-
nism depends on specific D genes optimized for cysteine pair-
ing, whereas, in the present case, cysteine diversity derives
from SHM within a single lineage.
To investigate the functional consequences of the clade
diversity, we analyzed neutralization fingerprints for a repre-
sentative selection of VRC01-lineage antibodies. Remarkably,
a dendrogram built to represent the neutralization (functional)
features mirrors dendrograms based on sequence phylogeny,
and, in particular, replicated the overall clade structure
(Figure S7D). Thus, the diverse clades do have functional differ-
ences that reflect their divergent sequences and the clade
organization.
Despite originating from a single ancestor B cell, different
clades of the VRC01 lineage have evolved substantial differ-
ences in disulfide-bonding patterns and sequence lengths for
some of their antigen-binding loops. The CDR H2—the central
contact surface of the antibody lineage with gp120—does not
vary in this manner, nor do other loops of the variable domains.
The peripheral role of both the CDR H3 and the FR3 region
in gp120 recognition may allow for extraordinary variation as
different antibody variants evolve to probe the gp120 surface
in distinctive ways.
DISCUSSION
It has been unclear how antibody lineages achieve the
unusually high levels of mutation commonly found for broadly
HIV-1-neutralizing antibodies. This led us to investigate the
evolutionary history of B cell lineages that produce such anti-
bodies. SHM and B cell selection are a form of ‘‘accelerated evo-
lution’’ that generates high-affinity antibodies. Inmost cases, this
process takes a few weeks and involves only a handful of muta-
tions, averaging about 5% nucleotide difference from the origi-
nating antibody genes. However, some broadly HIV-1-neutral-
izing antibodies are characterized by extraordinary levels of
SHM where >30% of nucleotides in the antibody variable region
differ from the germline-encoded sequence (Burton et al., 2012;
Kwong and Mascola, 2012; Mascola and Haynes, 2013). One
such antibody, VRC01 (Wu et al., 2010), was isolated approxi-
mately two decades after the donor was diagnosed with HIV-1
infection. Here, we used antibody isolation, NGS, and crystal
structures to characterize the VRC01 lineage from 1995–2009.
We observed extraordinary diversity, a result of a high rate of
SHM over years of chronic infection. Of note, several prior
studies indicated germline-reverted variants of VRC01-class an-
tibodies not to bind HIV-1 gp120, raising the question of how
they arise (Jardine et al., 2013; McGuire et al., 2013; Zhou
et al., 2010); our results indicate germline-reverted VRC01 to
bind an early autologous Env (d45-01dG5) (Wu et al., 2012), sug-
gesting the VRC01 lineage to have been initiated by interaction
with a specific autologous Env sequence (Figure S5C).
The NGS-derived sequences determined here are expected
to contain errors arising from cDNA preparation, PCR ampli-
fication, and 454 sequencing platform. We used the 454
pyrosequencing platform because its read lengths allowed iden-
tification of full variable region sequences. Unfortunately, theCell 161, 470–485, April 23, 2015 ª2015 Elsevier Inc. 481
sequencing reactions were error prone. We implemented qual-
ity-control procedures to reduce errors (Extended Experimental
Procedures) and to parse the NGS-derived data into three levels
of experimental certainty. First, ‘‘raw’’ VRC01-lineage se-
quences, from all ten time points, comprise 124,834 heavy-
chain and 28,500 light-chain sequences. Based on prior pub-
lished data, these sequences are expected to have an RMS er-
ror in sequence of 1.38% (Zhu et al., 2012). Second, ‘‘curated’’
sequences comprise 1,041 heavy- and 492 light-chain se-
quences, and, of these, 162 heavy-chain and 119 light-chain se-
quences were observed to have biological replicates at the
97.25% level in other time points. Third, ‘‘confirmed neutral-
izers’’ comprise the closest to consensus or most highly repre-
sented sequences, and these are expected to have median ac-
curacy in sequence of 98.9% identity based on the accuracy of
VRC01-class plasmids (Extended Experimental Procedures).
Additionally, 36% of the confirmed neutralizing sequences had
temporal biological replicates at >97.25% identity. Finally, we
note that evolutionary rate calculations were performed with
curated sequences, and the results were similar over multiple
bootstraps, suggesting that these calculated rates were not
substantially affected by NGS-sequence errors. Thus, the
‘‘leaves’’ of the VRC01-lineage phylogenetic tree and raw data
(Figure 2) contain substantial uncertainty, while the overall clade
structure (Figures 4 and 7) (which is defined by the confirmed
neutralizers and probe-identified antibodies and consists of
clades that differ on average by 40%–50% in sequence) and
overall rate of evolution (Figure 6) should not be substantially
affected by errors in the NGS data.
Despite the substantial differences between clades of the
VRC01 lineage, their average divergences were similar at each
time point, and they also showed similar evolutionary rates (Fig-
ure 6A). Antibody lineages unrelated to the VRC01 lineage, how-
ever, showed substantially different evolutionary rates. Thus,
each member of a lineage appeared to share common rate char-
acteristics. Notably, this rate does not appear to be influenced by
the differing neutralization of the individual clades on autologous
virus (Wu et al., 2012), as might be expected from the co-evolu-
tion of virus and neutralizing antibody (Richman et al., 2003; Wei
et al., 2003). These finding suggest that the criteria for continued
maturation may be less stringent than the criteria for effective
neutralization and that the rate of antibody evolutionmay depend
on the number of cell divisions from the single originating com-
mon ancestor B cell.
Our data suggest that the evolutionary rate of an antibody
lineage slows as it matures. Importantly, even the lowest rates
of antibody evolution that we observed were comparable to the
evolutionary rate of HIV-1 Env. For the 01+07 clade, heavy
chains had already mutated to 20% divergence at the earliest
study time point, and we observed continuous SHM to >30%
at the end study point (Figure S6A). Likewise, the levels of
SHM for other heavy-chain and light-chain clades of the line-
age also increased over time, despite high initial divergence.
These data suggest that SHM may continue for as long as an-
tigen persists in long-term chronic infection. The rapid evolu-
tionary rates described here, combined with persistent antigen
due to chronic infection over years, provide a mechanism to
explain how antibodies can develop the high levels of SHM482 Cell 161, 470–485, April 23, 2015 ª2015 Elsevier Inc.and lineage diversity required for broad and potent neutraliza-
tion of HIV-1.
Previously described antibodies from the VRC01 lineage of
donor 45 were diverse enough that they appeared to represent
several separate lineages (Wu et al., 2010, 2011). Here, we
show that the diversity of the VRC01 lineage extends far beyond
what has generally been thought possible, comprising at least
six distinct heavy-chain clades and five light-chain clades. The
curated deep-sequencing data fill in details of this clade struc-
ture, without deviating from the outlines provided by functionally
validated sequences and antibodies (Figure S7E). Each clade
had distinctive sequence and structure characteristics. CDR
H3 length within the lineage ranged from 9 to 23 residues, and
CDR H3 cysteines ranged from a single cysteine, which formed
an interloop disulfide with another CDR, to four cysteines, which
formed two intraloop disulfides (Figure 7B). This diversity and its
continued evolution present a picture of antibody immunity in
which extraordinary variation within just a few antibody line-
ages—or even a single lineage—may be of critical importance
for opposing HIV-1.
EXPERIMENTAL PROCEDURES
Human Specimens
Recovery of PBMCs from donor 45 (Li et al., 2007; Wu et al., 2010) has been
described previously. Donor 45 samples from different time points were
collected with informed consent under clinical protocols approved by the
appropriate institutional review board (IRB).
Isolation of Donor 45 Antibodies
Fluorescence-activated cell sorting of antigen-specific IgG+ B cells from donor
45 PBMC and the amplification and cloning of immunoglobulin genes were
carried out using previously described protocols (Wu et al., 2010).
Expression and Purification of Antibodies and Fab Fragments
Expression plasmids for heavy and kappa chains were constructed as
described previously (Zhou et al., 2010). The expression and purification of
antibody IgGs and preparation of Fab fragments were carried out as described
in Extended Experimental Procedures.
Neutralization Assessment
Neutralization of donor 45 antibodies were measured using single-round-of-
infection HIV-1 Env pseudoviruses and TZM-bl target cells using protocols
described in Extended Experimental Procedures.
Crystallization, X-RayDataCollection, StructureDetermination, and
Refinement of Donor 45 Antibodies in Complex with HIV-1 gp120
Purification, crystallization of antibody-gp120 complexes, and data collection
are described in Extended Experimental Procedures. All diffraction data
were integrated and scaled with the HKL2000 suite (Otwinowski and Minor,
1997). Structure solution, refinement, and analysis are described in Extended
Experimental Procedures.
454 Pyrosequencing
454 pyrosequencing libraries from donor 45 were prepared and 454 pyrose-
quencing of the PCR products were performed with modifications to those
described previously (Wu et al., 2011) and in Extended Experimental
Procedures.
Bioinformatics Analysis
Bioinformatics analyses of the longitudinal 454 data were performed using al-
gorithms similar to those described previously (Zhu et al., 2013), implemented
in a new Python code base. Data-quality filtering and other new bioinformatics
methods are described in Extended Experimental Procedures.
ACCESSION NUMBERS
Coordinates and structure factors for the eight antibody-HIV-1 gp120 complex
structures have been deposited in the Protein Data Bank with accession
numbers 4XVS, 4XVT, 4S1Q, 4S1R, 4S1S, 4XNZ, 4XMP, and 4XNY. Raw
454 data have been deposited in the NCBI Short Reads Archive with accession
number SRP052625. In addition, 1,041 curated heavy-chain sequences
(accession numbers KP840719–KP841751), 33 functionally validated NGS-
derived heavy-chain sequences (accession numbers KP840592–KP840624 ),
492 curated light-chain sequences (accession numbers KP841752–
KP842237 ), 32 functionally validated NGS-derived light-chain sequences
(accession numbers KP840625–KP840656 ), and 31 new probe-identified an-
tibodies with both heavy- and light-chain sequences (accession numbers
KP840657–KP840687 and KP840688–KP840718, respectively ) have been
deposited in GenBank.
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